Gland Pharma Secures USFDA Approval for Generic Corticosteroid Injection, Expands Presence in $214 Million US Market

Indian pharmaceutical manufacturer Gland Pharma Limited has received approval from the United States Food and Drug Administration (USFDA) for Methylprednisolone Acetate Injectable Suspension USP, strengthening its portfolio of sterile injectable medicines in the regulated American pharmaceutical market. The approval covers multiple strengths and vial presentations of the corticosteroid medicine, which is used in the management of inflammatory, allergic and several other medical conditions.

In an official announcement submitted to the stock exchanges on November 3, Gland Pharma confirmed that the USFDA had approved its Abbreviated New Drug Application (ANDA) for the injectable formulation. The approved product is bioequivalent and therapeutically equivalent to Depo-Medrol Injectable Suspension, the reference-listed medicine manufactured by Pfizer Inc.

According to IQVIA market data cited by the company, methylprednisolone injectable products covered by the announcement recorded approximately USD 214 million in United States sales during the twelve months ending August 2026. The regulatory clearance creates an opportunity for Gland Pharma to expand its participation in the American corticosteroid medicines market while strengthening India’s presence in the international sterile injectables industry.

USFDA Approves Single-Dose and Multiple-Dose Injectable Formulations

The USFDA approval covers Methylprednisolone Acetate Injectable Suspension USP in two single-dose vial strengths, 40 mg/mL and 80 mg/mL, along with three multiple-dose vial presentations.

The approved multiple-dose presentations include 200 mg/5 mL and 400 mg/10 mL formulations containing 40 mg/mL of the active pharmaceutical ingredient, as well as a 400 mg/5 mL formulation containing 80 mg/mL.

The availability of different vial presentations allows healthcare providers to select appropriate product configurations based on prescribed treatment requirements and authorised administration procedures.

Methylprednisolone acetate is a long-acting corticosteroid that helps control inflammation and suppress excessive immune responses. Its therapeutic applications include the management of selected allergic conditions, dermatological diseases, endocrine disorders, respiratory conditions, rheumatic diseases and other disorders for which corticosteroid treatment is clinically indicated.

The medicine is used under medical supervision, with the appropriate dose and route of administration determined by the patient’s condition and the approved prescribing information.

Generic Equivalent of Pfizer’s Depo-Medrol

Gland Pharma’s approved formulation is a generic equivalent of Pfizer’s Depo-Medrol Injectable Suspension, an established corticosteroid medicine used in clinical practice.

The USFDA’s ANDA approval process enables pharmaceutical companies to introduce generic alternatives to previously approved medicines after demonstrating compliance with applicable regulatory requirements.

For Gland Pharma, the approval confirms that its formulation has satisfied the requirements for bioequivalence and therapeutic equivalence to the reference-listed product.

Generic injectable medicines play an important role in pharmaceutical supply chains by providing additional sources of established treatments. Their availability can increase competition among manufacturers and support healthcare providers in maintaining access to essential medicines.

The development is particularly relevant to India’s pharmaceutical industry because sterile injectable medicines require specialised manufacturing infrastructure, stringent quality controls and comprehensive regulatory compliance.

Advanced Sterile Manufacturing Strengthens India’s Pharmaceutical Capabilities

Manufacturing injectable corticosteroid suspensions requires expertise in sterile pharmaceutical production, formulation development and the control of critical product characteristics.

Unlike conventional oral medicines, injectable products must meet stringent requirements for sterility, particulate control, pharmaceutical stability and manufacturing consistency. Suspension formulations introduce additional technical considerations because the active pharmaceutical ingredient must remain appropriately distributed within the liquid preparation.

Manufacturers must carefully manage particle characteristics, formulation stability and processing conditions to ensure that products meet their approved quality specifications.

Gland Pharma has developed substantial capabilities in sterile injectable manufacturing, including vials, ampoules, prefilled syringes, lyophilised formulations and other specialised pharmaceutical presentations.

The company’s experience in developing and manufacturing injectable medicines has enabled it to establish a presence in regulated international markets, including the United States, Europe, Canada and Australia.

The latest approval adds another product to its American pharmaceutical portfolio and demonstrates the continuing importance of specialised drug manufacturing capabilities within India’s pharmaceutical industry.

US Corticosteroid Market Represents Significant Commercial Opportunity

According to IQVIA data cited in the company’s announcement, methylprednisolone injection products generated approximately USD 214 million in United States sales during the twelve-month period ending August 2026.

The figure highlights the established commercial demand for this category of injectable corticosteroid medicines.

The USFDA approval provides Gland Pharma with an opportunity to participate in this market through its generic formulation, subject to commercial launch arrangements, distribution requirements and market competition.

For Indian pharmaceutical manufacturers, regulatory approvals in the United States are important because the market maintains demanding requirements for pharmaceutical quality, manufacturing processes and product documentation.

The ability to obtain approvals for specialised injectable formulations contributes to the international competitiveness of India’s pharmaceutical industry, particularly in product categories requiring advanced manufacturing capabilities.

Gland Pharma’s continuing focus on sterile injectables positions the company within a segment of the pharmaceutical industry where technological expertise and regulatory compliance are essential for sustained international participation.

Gland Pharma Expands International Generic Medicines Portfolio

Established in Hyderabad in 1978, Gland Pharma has developed from a manufacturer of small-volume injectable products into an international pharmaceutical company specialising in sterile formulations.

The company operates primarily through a business-to-business model, supplying pharmaceutical products to partners and distributors across international markets.

Its product portfolio encompasses several therapeutic categories and manufacturing formats, including sterile injectables, oncology medicines and ophthalmic formulations.

The latest approval reflects Gland Pharma’s continued development of pharmaceutical products intended for regulated markets, where manufacturers must demonstrate compliance with stringent standards before commercial distribution.

The company’s activities also contribute to India’s wider pharmaceutical manufacturing ecosystem through demand for research expertise, pharmaceutical ingredients, analytical testing, specialised packaging and advanced production equipment.

India’s growing capabilities in complex injectable medicines represent an important extension of the country’s established strengths in generic pharmaceutical manufacturing.

USFDA Approval Reinforces India’s Sterile Injectables Manufacturing Presence

Gland Pharma’s approval for Methylprednisolone Acetate Injectable Suspension represents another regulatory milestone for India’s pharmaceutical industry, demonstrating the ability of domestic manufacturers to develop specialised formulations meeting international quality requirements.

The clearance covers five single-dose and multiple-dose vial presentations and establishes regulatory equivalence with Pfizer’s reference-listed Depo-Medrol product.

With the relevant American market valued at approximately USD 214 million annually, the approval creates an additional commercial opportunity for the Hyderabad-based company while expanding the range of generic injectable medicines available to the US healthcare market.

The development highlights the contribution of Indian pharmaceutical manufacturing expertise to international medicine supply chains, particularly in specialised therapeutic categories requiring advanced formulation science, sterile production capabilities and regulatory compliance.

Gland Pharma’s latest USFDA approval strengthens India’s position in the global sterile injectables industry and reinforces the growing contribution of Indian pharmaceutical companies to the development and supply of regulated generic medicines.

---